COVID-19 Drug Development

J Microbiol Biotechnol. 2022 Jan 28;32(1):1-5. doi: 10.4014/jmb.2110.10029.

Abstract

Diagnostics, vaccines, and drugs are indispensable tools and control measures employed to overcome infectious diseases such as coronavirus disease 2019 (COVID-19). Diagnostic tools based on RT-PCR were developed early in the COVID-19 pandemic and were urgently required for quarantine (testing, tracing and isolation). Vaccines such as mRNA vaccines and virus-vectored vaccines were also successfully developed using new platform technologies within one year after identifying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the causative agent of COVID-19. Drug development has been conducted in various ways including drug repurposing, convalescent plasma therapy, and monoclonal antibody development. Among the above efforts, this review examines COVID-19 drug development along with the related and upcoming challenges.

Keywords: COVID-19; SARS-CoV-2; convalescent plasma; drug repurposing; monoclonal antibody.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Viral / blood
  • Antiviral Agents / chemistry
  • Antiviral Agents / therapeutic use*
  • COVID-19 / drug therapy*
  • COVID-19 / prevention & control
  • COVID-19 / therapy*
  • Drug Development*
  • Drug Repositioning / methods*
  • Humans
  • Immunization, Passive
  • SARS-CoV-2 / drug effects*
  • SARS-CoV-2 / genetics

Substances

  • Antibodies, Monoclonal
  • Antibodies, Viral
  • Antiviral Agents